ClinicalTrials.gg
Active, not recruitingNCT04699721Updated Oct 2, 2026

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

A Phase 2 interventional study of Probiotics (BiFico)+nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5 in Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA and Non-small Cell Lung Cancer Stage IIIB, sponsored by Xiangya Hospital of Central South University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Xiangya Hospital of Central South University · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2020, registered Dec 2020).
Updated Oct 2, 2026Start date movedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 988 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Enrollment
980th of 1,597
65 · median 100
Started
2020
with 134 others
Phase 2
653 of 1,885
274 open now
Primary completion
2024-12
later than 130 of 987 live
Registered
771st of 1,885
by date

Among the 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 980th largest by enrollment of the 1,597 interventional ones that give a count, is one of 135 that started in 2020, is one of 653 in phase 2, reaches primary completion later than 130 of the 987 other live ones, and was the 771st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,885 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics for resectable NSCLC patients.

03

Conditions studied

  • Non-small Cell Lung Cancer Stage II
  • Non-small Cell Lung Cancer Stage ⅢA
  • Non-small Cell Lung Cancer Stage IIIB

Keywords

  • Neoadjuvant therapy
  • Immunotherapy
  • Chemotherapy
  • Probiotics
  • Non-small cell lung cancer (NSCLC)
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed previously untreated non-small cell lung cancer.
  2. Patients with resectable stage II, IIIA and IIIB (N2) disease (according to AJCC 8th edition);
  3. (ECOG) performance status score 0-1;
  4. 18 years ≤ Age ≤ 80 years;
  5. Patients with appropriate treatment compliance and could be followed-up correctly;
  6. Patients with measurable or evaluable diseases (according to 1.1);
  7. Patients must have the ability to swallow oral drugs;
  8. Patients with adequate pulmonary function capable of tolerating the proposed lung resection according to the evidence-based clinical practice guidelines of American College of Chest Physicians;
  9. Signed and dated written must be provided by the patient prior to admission to the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known ALK translocations or EGFR mutations.
  2. Subjects with active, known or suspected disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll;
  3. Subjects with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease;
  4. Patients with symptomatic ILD (grade 3-4) and/or poor lung function and a history of interstitial lung disease cannot be included;
  5. Patients with other active malignant tumors currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or anti-cancer drug;
  6. Patients who are unable to follow the procedures required in the protocol due to any medical, mental or psychological conditions;
  7. Prior treatment with an , anti-PD-L1 or anti-CTLA-4 antibody or any other antibodies or drugs that target T cell costimulation or immune checkpoint pathways;
  8. Known positive test for virus surface antigen (HBV sAg) or virus ribonucleic acid indicating acute or chronic infection;
  9. Known history of testing positive for or known acquired immunodeficiency syndrome;
  10. Patients with a history of allergy to study drugs or ingredients.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Arm 1

    3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)

    Drug: Probiotics (BiFico)+nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5

Interventions

This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Pathological complete response

    The percentage of participants with 0% residual viable tumor cells in the primary tumor and sampled lymph nodes after neoadjuvant therapy.

    Time frame: After surgery, based on surgical resection specimens and blinded independent pathological review.

Secondary outcomes

  1. Objective response rate

    The percentage of participants who achieved complete response or partial response after 3 cycles of neoadjuvant therapy according to the RECIST 1.1 criteria.

    Time frame: 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.

  2. Clinical TNM downstaging

    Participants who achieve a a reduction in the corresponding radiological T, N, or overall TNM stage compared with baseline.

    Time frame: 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.

  3. Treatment-related Adverse Events

    The number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: Treatment-related adverse events were assessed between the start of the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment.

  4. Disease free survival

    The time (month) from the completion of lung cancer radical surgery to the recurrence or metastasis of the disease.

    Time frame: 1 year, 3 years and 5 years after the operation

  5. Recurrence rate

    The percentage of participants who have recurrence or metastasis of lung cancer at certain time points after radical surgery.

    Time frame: 1 year, 3 years and 5 years after the operation

  6. Overall survival

    The time (month) from the completion of lung cancer radical surgery to all-cause death.

    Time frame: 1 year, 3 years and 5 years after the operation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication

Supporting information: Study protocol

Time frame: IPD will be shared when the clinical trail is finished

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2024, 51 months.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 51 months is close to that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start Jul 2020 → Sep 2020 and primary completion Sep 2027 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2020
First posted
Jan 7, 2021
StartActual
Sep 2, 2020was Jul 2020
Primary completionActual
Dec 31, 2024was Sep 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2020→Sep 2, 2020
Oct 2, 2026
Primary completion
Sep 2027→Dec 31, 2024 (actual)
Oct 2, 2026
Enrollment
60 (estimated)→65 (actual)
Oct 2, 2026
Eligibility
3 inclusion criteria edited, 1 added; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • AddedHistologically or cytologically confirmed previously untreated non-small cell lung cancer.
  • EditedHistologically or cytologically confirmed previously untreated non-small cell lung cancer. Patients with resectable stage II, IIIA and potentially resectable stage IIIB (T3N2N2) disease (according to AJCC 8th edition) are eligible ;
  • ChangedBefore 18 years ≤ Age ≤ 80 years. Signed and dated written informed consent must be provided by the patient prior to admission to the study;Now 18 years ≤ Age ≤ 80 years;
  • EditedPatients with adequate pulmonary function capable of tolerating the proposed lung resection (as determined byaccording to the surgeon)evidence-based clinical practice guidelines of American College of Chest Physicians;
Exclusion criteria
  • EditedPatients with symptomatic ILD (grade 3-4) and/or poor lung function and a history of interstitial lung disease cannot be included. If you have any questions, please contact the trial team;
  • EditedPatients who are inabilityunable to follow the procedures required in the protocol due to any medical, mental or psychological conditions;
Oct 2, 2026
Interventions
Changed nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5→Probiotics (BiFico)+nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5
Oct 2, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time framePathological complete responseWithin 3 days after the operation → After surgery, based on surgical resection specimens and blinded independent pathological review.
  • DescriptionPathological complete response: how it is measured was reworded
Oct 2, 2026
Secondary outcomes
1 edited, 2 time frame changed, 3 removed, 1 description edited
What changed in the outcomes
  • ChangedBefore Adverse effectsNow Treatment-related Adverse EventsTime frame: Treatment-related adverse events were assessed between the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment. → Treatment-related adverse events were assessed between the start of the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment.
  • RemovedMajor Pathologic ResponseTime frame: Within 3 days after the operation
  • RemovedSurgical complications (intra-operative and peri-operative)Time frame: 90 days after the first medication or 30 days after the operation, whichever is later
  • RemovedR0 surgical eventsTime frame: 28 days after the completion of three cycles of neoadjuvant therapy
  • Time frameObjective response rate28 days after the completion of three cycles of neoadjuvant therapy and before the operation → 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
  • Time frameClinical TNM downstaging28 days after the completion of three cycles of neoadjuvant therapy and before the operation → 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
  • DescriptionClinical TNM downstaging: how it is measured was reworded
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Start date Jul 1, 2020→Sep 2, 2020
    Primary completion Sep 2027→Dec 31, 2024 (now actual)
    Enrollment 60 (estimated)→65 (actual)
    Eligibility 3 inclusion criteria edited, 1 added; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • AddedHistologically or cytologically confirmed previously untreated non-small cell lung cancer.
    • EditedHistologically or cytologically confirmed previously untreated non-small cell lung cancer. Patients with resectable stage II, IIIA and potentially resectable stage IIIB (T3N2N2) disease (according to AJCC 8th edition) are eligible ;
    • ChangedBefore 18 years ≤ Age ≤ 80 years. Signed and dated written informed consent must be provided by the patient prior to admission to the study;Now 18 years ≤ Age ≤ 80 years;
    • EditedPatients with adequate pulmonary function capable of tolerating the proposed lung resection (as determined byaccording to the surgeon)evidence-based clinical practice guidelines of American College of Chest Physicians;
    Exclusion criteria
    • EditedPatients with symptomatic ILD (grade 3-4) and/or poor lung function and a history of interstitial lung disease cannot be included. If you have any questions, please contact the trial team;
    • EditedPatients who are inabilityunable to follow the procedures required in the protocol due to any medical, mental or psychological conditions;
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time framePathological complete responseWithin 3 days after the operation → After surgery, based on surgical resection specimens and blinded independent pathological review.
    • DescriptionPathological complete response: how it is measured was reworded
    Secondary outcomes 1 edited, 2 time frame changed, 3 removed, 1 description edited
    What changed in the outcomes
    • ChangedBefore Adverse effectsNow Treatment-related Adverse EventsTime frame: Treatment-related adverse events were assessed between the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment. → Treatment-related adverse events were assessed between the start of the first neoadjuvant dose and 30 days after the last dose of neoadjuvant study treatment.
    • RemovedMajor Pathologic ResponseTime frame: Within 3 days after the operation
    • RemovedSurgical complications (intra-operative and peri-operative)Time frame: 90 days after the first medication or 30 days after the operation, whichever is later
    • RemovedR0 surgical eventsTime frame: 28 days after the completion of three cycles of neoadjuvant therapy
    • Time frameObjective response rate28 days after the completion of three cycles of neoadjuvant therapy and before the operation → 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
    • Time frameClinical TNM downstaging28 days after the completion of three cycles of neoadjuvant therapy and before the operation → 21 days (±7 days) after the completion of three cycles of neoadjuvant therapy and before surgery.
    • DescriptionClinical TNM downstaging: how it is measured was reworded
    Interventions Changed nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5→Probiotics (BiFico)+nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5
    + 4 other changes: verification date, description, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04699721
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Sep 2, 2020
Primary completion
Dec 31, 2024
Completion
Dec 31, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Yang Gao, Doctor
study director · Xiangya Hospital of Central South University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis Probiotic Supplement · Nivolumab

Start the discussion